Thymogen: Two Amino Acids, Approved in Russia
A dipeptide from the thymic line of the Khavinson programme — one of the six peptide pharmaceuticals introduced into Soviet clinical practice, and among the shortest molecules ever registered as a medicine.
What Is Thymogen?
Thymogen is a dipeptide — Glu-Trp, glutamic acid joined to tryptophan — developed within the thymic branch of the Khavinson programme alongside Thymalin and Vilon.
How short a medicine can be, in plain language: most medicines are elaborate structures. A typical small-molecule drug has dozens of atoms arranged in rings and branches; a biologic can be a protein of hundreds of amino acids. Thymogen is two amino acids. If a protein drug is a cathedral, this is a pair of bricks. Whether something that small can carry a specific enough instruction to be useful is the question the whole bioregulator programme rests on — and Thymogen is one of the few places where a regulator, in one country at least, decided the answer was yes.
What the Research Examines
Thymogen was one of six peptide preparations introduced into medical practice in the USSR during the 1980s, indicated as an immunomodulator. That regulatory history is genuine and is worth stating, though it applies to a specific pharmaceutical product in Russia and does not extend to the TGA, FDA or EMA.
Published research examines effects on immune cell function and on markers of adaptive immunity, largely in the Russian-language literature and originating chiefly from the developing institute. Independent Western replication is limited.
A Peptide for an Organ That Disappears
The thymus behaves unlike any other organ in the body, and understanding why makes the entire thymic line of the Khavinson programme easier to place.
It sits behind the breastbone and is at its largest and busiest in childhood. Its job is training — immune cells arrive immature and are taught, with considerable rigour, to distinguish the body from everything else. Cells that fail the test are destroyed, and the great majority fail.
Then it shrinks. From adolescence onward the thymus progressively shrivels and is replaced with fatty tissue. By later life very little functional thymus remains. It is the only organ that is meant to do this.
Think of scaffolding around a building under construction. While the structure is going up the scaffolding is essential and highly visible. Once it is standing, the scaffolding comes down — not because it failed, but because its work is finished. Whether that is good design or an accident nobody ever corrected is genuinely argued over.
That decline is why the thymus attracts ageing research, and it is also the reason to be careful. Something declining with age is a reason to investigate, not evidence that restoring it helps. The same inference has failed elsewhere often enough to be worth naming.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
- Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
- Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
- Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed
Related Research Guides
More in Bioregulators & Neuropeptides
The whole Khavinson system — one peptide per organ, and the honest state of the evidence.
Read guide →Thymic Peptide ExtractThe first-generation thymus extract from the same research line.
Read guide →Thymic DipeptideThe other synthesised thymic dipeptide, Lys-Glu.
Read guide →